TY - JOUR
T1 - Theory-based diabetes self-management education with pre-selection of participants
T2 - a randomized controlled trial with 2.5 years’ follow-up (ELDES Study)
AU - Vos, R. C.
AU - van Heusden, L.
AU - Eikelenboom, N. W.D.
AU - Rutten, G. E.H.M.
N1 - Funding Information:
This work was supported by the European Foundation for the Study of Diabetes (EFSD) with an educational research grant (EFSD/AZ-BMS Grant 2013).
Publisher Copyright:
© 2019 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Aims: To evaluate the (cost-)effectiveness of Beyond Good Intentions (BGI), a 12-week group-based, nurse-led self-management programme, in terms of cardiovascular risk factors, self-management and quality of life, after 2.5 years of follow-up in pre-selected individuals with known Type 2 diabetes of up to 5 years’ duration. Methods: A parallel randomized controlled trial comparing BGI with usual care, based on a self-management screening questionnaire, was conducted in 43 general practices after pre-selection of participants. After 2.5 years of follow-up, the between-group changes in the abovementioned variables were assessed using analysis of covariance. Results: A total of 108 participants (BGI group, n =56; control group, n =52) were included. Changes over time in BMI (–0.4 vs –0.5 kg/m2) were similar in the two groups. Median HbA1c [BGI group 47 mmol/mol (6.5%); control group: 49 mmol/mol (6.6%)] and mean systolic blood pressure (BGI group: 132±13 mmHg; control group: 133±14 mmHg) were well controlled at baseline and no intervention effect was found. LDL cholesterol levels decreased from 2.4 to 2.2 mmol/l in the control group and remained stable at 2.6 mmol/l in the intervention group (P=0.032). No intervention effect was found for self-management or quality of life. Conclusion: In contrast to the first BGI study, we did not observe significant effects of the BGI intervention, despite pre-selection of individuals. In diabetes populations with target levels for HbA1c, systolic blood pressure and LDL cholesterol, no further beneficial effects can be expected from self-management programmes with regard to biomedical factors and quality of life.
AB - Aims: To evaluate the (cost-)effectiveness of Beyond Good Intentions (BGI), a 12-week group-based, nurse-led self-management programme, in terms of cardiovascular risk factors, self-management and quality of life, after 2.5 years of follow-up in pre-selected individuals with known Type 2 diabetes of up to 5 years’ duration. Methods: A parallel randomized controlled trial comparing BGI with usual care, based on a self-management screening questionnaire, was conducted in 43 general practices after pre-selection of participants. After 2.5 years of follow-up, the between-group changes in the abovementioned variables were assessed using analysis of covariance. Results: A total of 108 participants (BGI group, n =56; control group, n =52) were included. Changes over time in BMI (–0.4 vs –0.5 kg/m2) were similar in the two groups. Median HbA1c [BGI group 47 mmol/mol (6.5%); control group: 49 mmol/mol (6.6%)] and mean systolic blood pressure (BGI group: 132±13 mmHg; control group: 133±14 mmHg) were well controlled at baseline and no intervention effect was found. LDL cholesterol levels decreased from 2.4 to 2.2 mmol/l in the control group and remained stable at 2.6 mmol/l in the intervention group (P=0.032). No intervention effect was found for self-management or quality of life. Conclusion: In contrast to the first BGI study, we did not observe significant effects of the BGI intervention, despite pre-selection of individuals. In diabetes populations with target levels for HbA1c, systolic blood pressure and LDL cholesterol, no further beneficial effects can be expected from self-management programmes with regard to biomedical factors and quality of life.
UR - http://www.scopus.com/inward/record.url?scp=85061640802&partnerID=8YFLogxK
U2 - 10.1111/dme.13907
DO - 10.1111/dme.13907
M3 - Article
C2 - 30677175
AN - SCOPUS:85061640802
SN - 0742-3071
VL - 36
SP - 827
EP - 835
JO - Diabetic Medicine
JF - Diabetic Medicine
IS - 7
ER -